Company intelligence / Profile preview
Propanc Biopharma, Inc.
Camberwell, Australiapropanc.com ↗
- Ownership
- Public · PPCB
- Employees
- ~2
- Development stage
- Preclinical
01
Overview
The company is developing PRP, a novel formulation of two proenzymes (trypsinogen and chymotrypsinogen) that targets solid tumors. A compassionate use study with 46 patients with advanced metastatic cancers showed 41.3% of patients had significantly longer survival time than expected (9.0 months vs 5.6 months life expectancy) with no severe adverse events. The company is preparing for Phase 1b First-in-Human clinical trials.
- Therapeutic areas
- Oncology
- Modalities
- Pancreatic proenzymesRecombinant proenzymes
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
University of JaénUniversity of GranadaBath UniversityvivoPharmQ Biologicalsibs.GRANADAAndalusian Public Foundation (FIBAO)
04
Financials
- Market cap
- $1.7M
- Total revenue
- $0
- Enterprise value
- $1.4M
Beyond the preview
Go deeper on Propanc Biopharma, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Propanc Biopharma, Inc..